Protagonist Therapeutics Inc. (PTGX)

Overview

Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on the development of peptide-based drugs to address unmet medical needs in the areas of hematology and blood disorders, as well as inflammatory and immunomodulatory diseases. Incorporated in 2006, the company has dedicated its research and development efforts to create innovative treatments, leveraging its expertise in peptide technology. Headquartered in Newark, California, Protagonist Therapeutics stands at the forefront of drug development, working in collaboration with industry leaders such as Takeda and JNJ Innovative Medicines to bring new therapies to market.

Products and Services

List of key developmental drugs and collaborations:

• Rusfertide (PTG-300): An injectable hepcidin mimetic designed for the treatment of polycythemia vera and other blood disorders. Rusfertide has completed phase 2 clinical trials, showing promise as a novel therapeutic option. This development is part of a licensing and commercialization agreement with Takeda, aiming to make a significant impact on patients' lives by addressing the unmet needs in hematology.
• JNJ-2113: This orally delivered investigational drug is designed to block biological pathways involved in moderate-to-severe plaque psoriasis. Having completed phase 2b clinical trials, JNJ-2113 is developed in collaboration with JNJ Innovative Medicines. The partnership focuses on co-developing this Interleukin-23 receptor antagonist compound, which represents a novel approach to treating inflammatory diseases.
• PN-943: An orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, PN-943 has completed a phase 2 clinical trial for patients with moderate to severe ulcerative colitis. This drug aims to offer a targeted therapeutic approach, reducing the systemic side effects often associated with current treatments for this chronic and debilitating condition.